Lyra Debt Equity Ratio from 2010 to 2024

LYRA Stock  USD 0.21  0.01  5.00%   
Lyra Therapeutics' Debt Equity Ratio is increasing over the years with slightly volatile fluctuation. Overall, Debt Equity Ratio is expected to go to 0.06 this year. From 2010 to 2024 Lyra Therapeutics Debt Equity Ratio quarterly data regression line had arithmetic mean of  0.02 and r-squared of  0.50. View All Fundamentals
 
Debt Equity Ratio  
First Reported
2010-12-31
Previous Quarter
0.0607694
Current Value
0.0638
Quarterly Volatility
0.01729592
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lyra Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lyra Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 4.3 M, Interest Income of 4.3 M or Depreciation And Amortization of 467.5 K, as well as many indicators such as Price To Sales Ratio of 106, Dividend Yield of 0.0 or PTB Ratio of 2.77. Lyra financial statements analysis is a perfect complement when working with Lyra Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Lyra Therapeutics Correlation against competitors.
For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.

Latest Lyra Therapeutics' Debt Equity Ratio Growth Pattern

Below is the plot of the Debt Equity Ratio of Lyra Therapeutics over the last few years. It is Lyra Therapeutics' Debt Equity Ratio historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lyra Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Debt Equity Ratio10 Years Trend
Slightly volatile
   Debt Equity Ratio   
       Timeline  

Lyra Debt Equity Ratio Regression Statistics

Arithmetic Mean0.02
Geometric Mean0.02
Coefficient Of Variation79.68
Mean Deviation0.01
Median0.01
Standard Deviation0.02
Sample Variance0.0003
Range0.0506
R-Value0.71
Mean Square Error0.0002
R-Squared0.50
Significance0
Slope0
Total Sum of Squares0

Lyra Debt Equity Ratio History

2024 0.0638
2023 0.0608
2022 0.0243
2021 0.0313

About Lyra Therapeutics Financial Statements

Lyra Therapeutics stakeholders use historical fundamental indicators, such as Lyra Therapeutics' Debt Equity Ratio, to determine how well the company is positioned to perform in the future. Although Lyra Therapeutics investors may analyze each financial statement separately, they are all interrelated. For example, changes in Lyra Therapeutics' assets and liabilities are reflected in the revenues and expenses on Lyra Therapeutics' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Lyra Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Debt Equity Ratio 0.06  0.06 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Lyra Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Lyra Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Lyra Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Lyra Therapeutics Stock:
Check out the analysis of Lyra Therapeutics Correlation against competitors.
For information on how to trade Lyra Stock refer to our How to Trade Lyra Stock guide.
You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyra Therapeutics. If investors know Lyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyra Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.49)
Revenue Per Share
0.023
Quarterly Revenue Growth
(0.64)
Return On Assets
(0.42)
Return On Equity
(1.86)
The market value of Lyra Therapeutics is measured differently than its book value, which is the value of Lyra that is recorded on the company's balance sheet. Investors also form their own opinion of Lyra Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Lyra Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyra Therapeutics' market value can be influenced by many factors that don't directly affect Lyra Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyra Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyra Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyra Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.